Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Phase 3

Completed

Conditions: Periodic Fevers Syndrome

Interventions: Biological: Canakinumab (AIN457)

First Posted Date: 2016-09-22

Last Posted Date: 2018-08-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT02911857

Locations: 🇯🇵
Novartis Investigative Site, Kyoto-city, Kyoto, Japan

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis

Completed

Conditions: RRMS
Multiple Sclerosis

Interventions: Other: Observational

First Posted Date: 2016-09-20

Last Posted Date: 2017-11-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 414

Registration Number: NCT02907281

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1

Completed

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Interventions: Biological: PDR001
Drug: EGF816
Biological: CJM112
Biological: ACZ885
Drug: TMT212

First Posted Date: 2016-09-14

Last Posted Date: 2022-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 283

Registration Number: NCT02900664

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center SC-3, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States

and more 2 locations

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

Phase 3

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: LCZ696 (Sacubitril/Valsartan)
Drug: Placebo of LCZ696 (Sacubitril/Valsartan)
Drug: Placebo of Enalapril
Drug: Enalapril

First Posted Date: 2016-09-14

Last Posted Date: 2020-09-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 621

Registration Number: NCT02900378

Locations: 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: MAK683

First Posted Date: 2016-09-14

Last Posted Date: 2024-10-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 139

Registration Number: NCT02900651

Locations: 🇺🇸
Uni Of TX MD Anderson Cancer Cntr Dept of Onc, Houston, Texas, United States
🇺🇸
UCSF ., San Francisco, California, United States
🇺🇸
UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States

and more 1 locations

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Phase 3

Completed

Conditions: Ankylosing Spondyloarthritis

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2016-09-12

Last Posted Date: 2020-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 458

Registration Number: NCT02896127

Locations: 🇬🇧
Novartis Investigative Site, Wigan, United Kingdom

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol acetate 75 μg
Drug: Indacaterol acetate 150 μg

First Posted Date: 2016-09-08

Last Posted Date: 2020-01-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 79

Registration Number: NCT02892019

Locations: 🇹🇷
Novartis Investigative Site, Ankara, Turkey

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

Phase 3

Completed

Conditions: Mild Asthma

Interventions: Drug: QMF149 150/80 μg
Drug: MF 200 μg

First Posted Date: 2016-09-08

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 802

Registration Number: NCT02892344

Locations: 🇻🇳
Novartis Investigative Site, Hai Phong, Vietnam

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1

Completed

Conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

Interventions: Biological: PDR001
Drug: QBM076
Drug: HDM201
Drug: LCL161
Drug: Everolimus
Drug: Panobinostat

First Posted Date: 2016-09-07

Last Posted Date: 2023-01-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 298

Registration Number: NCT02890069

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 7 locations

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Phase 2

Completed

Conditions: Pulmonary Sarcoidosis

Interventions: Drug: ACZ885
Drug: Placebo

First Posted Date: 2016-09-02

Last Posted Date: 2021-10-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02888080

Locations: 🇳🇱
Novartis Investigative Site, Rotterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy